account_balance
Investment manager · 13F filer · SEC CIK 1560009
Versant Venture Management, LLC
Reported value$163Mas of Jun 30, 2026
Positions8 0 new, 0 sold out
Top 10 weight100.0%GLUE alone is 47%
FiledAug 1243 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
This fund reports 8 stocks.
GLUEMonte Rosa Therapeutics, Inc.
47.3%
IPSCCentury Therapeutics, Inc.
18.3%
JBIOJade Biosciences, Inc.
13.6%Trimmed −35%
LENZLenz Therapeutics, Inc.
9.3%
CTNMContineum Therapeutics, Inc.
5.5%
CRSPCrispr Therapeutics AG
5.0%
SKYE0.9%GLUEMonte Rosa Therapeutics, Inc.
47.3%
IPSC18.3%JBIOJade Biosciences, Inc.
13.6%Trimmed −35%
LENZ9.3%CTNM5.5%CRSP5.0%Box size is the share of the fund. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 8 as a list
GLUE Monte Rosa Therapeutics, Inc. 47.3% HeldIPSC Century Therapeutics, Inc. 18.3% HeldJBIO Jade Biosciences, Inc. 13.6% Trimmed −35%LENZ Lenz Therapeutics, Inc. 9.3% HeldCTNM Contineum Therapeutics, Inc. 5.5% HeldCRSP Crispr Therapeutics AG 5.0% HeldSKYE Skye Bioscience, Inc. 0.9% Held
Tempest Therapeutics, Inc. 0.2% Held
What changed